Drug Pricing Reform In Medicare And Medicaid: Upcoming Regulatory Actions
Two highly anticipated proposed rules in Medicare Part D are scheduled for near-term release.
You may also be interested in...
Congressional inaction on drug pricing legislation has meant the Trump Administration is pursuing a menu of regulatory approaches. For the most part, that means slower and incremental change.
Approach offered as alternative to more disruptive changes to Part B's existing buy-and-bill system; more aggressive proposals include new iteration of competitive acquisition program and moving Part B drug coverage to Part D.